- Home
- NTLA vs WGO Comparison
NTLA vs WGO Comparison
Compare NTLA & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- WGO
- Stock Information
- Founded
- NTLA 2014
- WGO 1958
- Country
- NTLA United States
- WGO United States
- Employees
- NTLA N/A
- WGO N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- WGO Homebuilding
- Sector
- NTLA Health Care
- WGO Industrials
- Exchange
- NTLA Nasdaq
- WGO Nasdaq
- Market Cap
- NTLA 794.5M
- WGO 878.3M
- IPO Year
- NTLA 2016
- WGO N/A
- Fundamental
- Price
- NTLA $10.68
- WGO $31.53
- Analyst Decision
- NTLA Buy
- WGO Buy
- Analyst Count
- NTLA 19
- WGO 11
- Target Price
- NTLA $35.11
- WGO $39.30
- AVG Volume (30 Days)
- NTLA 4.9M
- WGO 869.2K
- Earning Date
- NTLA 08-07-2025
- WGO 06-25-2025
- Dividend Yield
- NTLA N/A
- WGO 4.31%
- EPS Growth
- NTLA N/A
- WGO N/A
- EPS
- NTLA N/A
- WGO N/A
- Revenue
- NTLA $45,569,000.00
- WGO $2,741,800,000.00
- Revenue This Year
- NTLA N/A
- WGO N/A
- Revenue Next Year
- NTLA N/A
- WGO $8.01
- P/E Ratio
- NTLA N/A
- WGO N/A
- Revenue Growth
- NTLA N/A
- WGO N/A
- 52 Week Low
- NTLA $5.90
- WGO $28.00
- 52 Week High
- NTLA $28.18
- WGO $65.65
- Technical
- Relative Strength Index (RSI)
- NTLA 69.70
- WGO 48.94
- Support Level
- NTLA $8.98
- WGO $28.49
- Resistance Level
- NTLA $11.08
- WGO $29.56
- Average True Range (ATR)
- NTLA 0.69
- WGO 1.24
- MACD
- NTLA 0.16
- WGO 0.10
- Stochastic Oscillator
- NTLA 88.96
- WGO 72.78
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About WGO Winnebago Industries Inc.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was nearly $3 billion in fiscal 2024. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 83% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total RV unit volume was 38,796 in fiscal 2024. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.